[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369443-105":59,"doc-detail-369443-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","concomitant-autoimmunity-and-late-cancers-in-adult-onset-immunodeficiency-due-to-neutralizing-anti-ifn-g-autoantibodies","Concomitant autoimmunity and late cancers in adult-onset immunodeficiency due to neutralizing anti-IFN-g autoantibodies","","Adult-onset immunodeficiency associated with neutralizing anti-IFN-g autoantibodies (nAIGA) is linked to opportunistic intracellular infections, but concurrent autoimmunity and later malignancies are rarely characterized in a systematic way. This study followed 50 patients diagnosed between 2014 and 2024, assessing anti-IFN-g titers, autoimmune markers, and cancer surveillance during longitudinal follow-up. Malignancy occurred in 25%, and 58% developed concomitant autoimmune diseases. Most patients had positive autoimmune markers and some required long-term immunomodulation; two outliers with persistently high neutralizing antibodies developed late malignancies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/concomitant-autoimmunity-and-late-cancers-in-adult-onset-immunodeficiency-due-to-neutralizing-anti-ifn-g-autoantibodies/369443/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/concomitant-autoimmunity-and-late-cancers-in-adult-onset-immunodeficiency-due-to-neutralizing-anti-ifn-g-autoantibodies/369443.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What condition does this study investigate in relation to nAIGA?","Question",{"text":113,"@type":114},"It investigates concomitant autoimmunity and late cancers in adult-onset immunodeficiency due to neutralizing anti-IFN-g autoantibodies (nAIGA).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the study cohort assembled and followed over time?",{"text":118,"@type":114},"The study included 50 nAIGA patients diagnosed between 2014 and 2024, with 33 retrospectively included before January 2022 and 17 prospectively enrolled since January 2022. All patients had regular follow-ups with assessments of anti-IFN-g titers, autoimmune markers, and cancer survey based on physician evaluation.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study find about autoimmune markers and cancer outcomes?",{"text":122,"@type":114},"Most patients had at least one positive autoimmune marker, and 58% were diagnosed with concomitant autoimmune diseases. Malignancy occurred in 25%, and while most patients showed decreasing nAIGA titers over time, two outliers with persistently high neutralizing antibodies developed late-onset malignancies.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},369443,1790485531,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","TYPE Original Research PUBLISHED 17 April 2025  \nDOI 10.3389/fimmu.2025.1526439  \nOPEN ACCESS  \nEDITED BY  \nRikard Holmdahl,  \nKarolinska Institutet (KI), Sweden  \nREVIEWED BY  \nSaul Oswaldo Lugo Reyes,  \nNational Institute of Pediatrics, Mexico Vijaya Knight,  \nUniversity of Colorado Anschutz Medical Campus, United States  \n*CORRESPONDENCE  \nAristine Cheng  \n [arischeng@ntuh.gov.tw](arischeng@ntuh.gov.tw)  \nRECEIVED 11 November 2024  \nACCEPTED 24 March 2025  \nPUBLISHED 17 April 2025  \nCITATION  \nTsai W-T, Cheng C-Y, Sun H-Y, Guo B-C, Chiang Y-C, Cheng C-F, Pan Y-H, Wu U-I, Wang J-T, Sheng W-H, Cheng A, Chen Y-Cand Chang S-C (2025) Concomitant autoimmunity and late cancers in  \nadult-onset immunodeﬁciency due to neutralizing anti-IFN-g autoantibodies. Front. Immunol. 16:1526439 .  \ndoi: 10.3389/fimmu.2025.1526439  \nCOPYRIGHT  \n© 2025 Tsai, Cheng, Sun, Guo, Chiang, Cheng, Pan, Wu, Wang, Sheng, Cheng, Chen and Chang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nConcomitant autoimmunity and late cancers in adult-onset immunodeﬁciency due to neutralizing anti-IFN-g autoantibodies  \nWan-Ting Tsai 1,2, Chih-Yun Cheng 3, Hsin-Yun Sun 1,  \nBei-Chia Guo 1, Ying-Chieh Chiang 1, Chiao-Feng Cheng 1,  \nYi-Hua Pan 1, Un-In Wu1, Jann-Tay Wang1, Wang-Huei Sheng 1, Aristine Cheng1*, Yee-Chun Chen 1 and Shan-Chwen Chang 1  \n1 Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 2 Department of Internal Medicine, Taipei City Hospital, Zhongxiao Branch, Taipei, Taiwan, 3 Department of Internal Medicine, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan  \nBackground: Opportunistic intramacrophagic infections are well-characterized in adult-onset immunodeﬁciency associated with neutralizing anti-IFN-g autoantibodies (nAIGA) .  \nObjective: Concomitant autoimmune and neo plastic diseases are rarely described.  \nMethods: This study included 50 patients diagnosed with adult-onset immunodeﬁciency due to nAIGA between 2014-2024 . Thirty-three were retrospectively included before January 2022, and 17 out of 295 screened patients were enrolled prospectively since January 2022 . Ten patients were excluded due to missing records. All patients had regular follow-ups; anti-IFN-gtiters, autoimmune markers and cancer survey were conducted according to the primary physician’s evaluation.  \nResults: The median age at diagnosis of adult-onset immunodeﬁciency was 57 years, and 53% were men. Malignancy occurred in 25%; genitourinary cancer predominated (n=4) . Most (93%) patients had at least one positive autoimmune marker. Fifty-eight percent of patients were diagnosed with concomitant autoimmune diseases, and women (65%) predominated. Anti-nuclear antibody was positive in 61%, lupus anticoagulant in 50%, whilst autoimmune thyroiditis markers in 43% . Twenty-two percent of patients required long-term immuno modulation including biologic agents such as rituxima b and daratumumab. Three patients (8%) died after a median interval of 9 .4 years due to sepsis (n=2) and aggressive urothelial cancer (n=1) . Most patients had decreasing nAIGA titers over time; two outliers with persistently high neutralizing antibodies developed late-onset malignancies.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nConclusion: Adult-onset immunodeﬁciency due to nAIGA is a syndrome associated with concomitant autoimmunity. Chronic infection and autoimmune-mediated inﬂammation may foster neoplastic changes, but the underlying mechanism is still undetermined. Autoimmune dis","cbCainaK9Fg5hPr8","https://ap.wps.com/l/cbCainaK9Fg5hPr8","pdf",1630284,11,"English","# Introduction\n## Rationale for studying nAIGA\n## Relationship to infections, autoimmunity, and cancer\n# Methods\n## Patient cohort and follow-up\n## Autoimmune markers, anti-IFN-g titers, and cancer surveillance\n# Results\n## Demographics and malignancy rates\n## Autoimmune marker positivity and concomitant autoimmune diseases\n## Immunomodulation needs and mortality\n# Conclusion\n## Clinical surveillance implications","[{\"question\":\"What condition does this study investigate in relation to nAIGA?\",\"answer\":\"It investigates concomitant autoimmunity and late cancers in adult-onset immunodeficiency due to neutralizing anti-IFN-g autoantibodies (nAIGA).\"},{\"question\":\"How was the study cohort assembled and followed over time?\",\"answer\":\"The study included 50 nAIGA patients diagnosed between 2014 and 2024, with 33 retrospectively included before January 2022 and 17 prospectively enrolled since January 2022. All patients had regular follow-ups with assessments of anti-IFN-g titers, autoimmune markers, and cancer survey based on physician evaluation.\"},{\"question\":\"What did the study find about autoimmune markers and cancer outcomes?\",\"answer\":\"Most patients had at least one positive autoimmune marker, and 58% were diagnosed with concomitant autoimmune diseases. Malignancy occurred in 25%, and while most patients showed decreasing nAIGA titers over time, two outliers with persistently high neutralizing antibodies developed late-onset malignancies.\"}]","Concomitant autoimmunity and late cancers in adult-onset immunodeficiency due to neutralizing anti-IFN-g autoantibodies | PDF",1790182695,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8de0fd40cf749d004b741dc33ede9c67.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6020ce0373746904ca3a6968ccd57fb1.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe2d1dc55ce6379a320f0afbca7dc20d.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0037fd8640cfaffb16df0848b0ab0ff5.webp",980,1385]